Title |
Intratympanic gentamicin treatment for Ménière’s disease: a randomized, double-blind, placebo-controlled trial on dose efficacy - results of a prematurely ended study
|
---|---|
Published in |
Trials, August 2014
|
DOI | 10.1186/1745-6215-15-328 |
Pubmed ID | |
Authors |
Hendrik G Bremer, Ingrid van Rooy, Bas Pullens, Carla Colijn, Inge Stegeman, Hester J van der Zaag-Loonen, Peter Paul van Benthem, Sjaak F L Klis, Wilko Grolman, Tjasse D Bruintjes |
Abstract |
Gentamicin is used as a therapeutic agent for Ménière's disease because of its vestibulotoxicity causing chemo-ablation of the vestibular sensory epithelia. Its use has increased in recent years. However, there is still no consensus about the dose regimen of gentamicin in the treatment of Ménière's disease. In this study two different dose regimen treatment protocols are compared in a placebo controlled study design. The primary objective is to quantify the treatment effect on dizziness, the secondary objective is hearing evaluation. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Korea, Republic of | 1 | 2% |
Unknown | 63 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 10 | 16% |
Student > Postgraduate | 9 | 14% |
Researcher | 6 | 9% |
Student > Doctoral Student | 6 | 9% |
Student > Bachelor | 6 | 9% |
Other | 13 | 20% |
Unknown | 14 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 34 | 53% |
Nursing and Health Professions | 3 | 5% |
Neuroscience | 2 | 3% |
Biochemistry, Genetics and Molecular Biology | 1 | 2% |
Agricultural and Biological Sciences | 1 | 2% |
Other | 5 | 8% |
Unknown | 18 | 28% |